Sharechat Logo

Oceania Healthcare Limited (NZX: OCA) DRP Strike Price for 2021 Interim Dividend

Tuesday 16th February 2021

Text too small?

Oceania Healthcare Limited advises that the strike price for the Dividend Reinvestment Plan (DRP) operating in respect of the dividend payable on 24 February 2021 has been set at NZ$1.5331 per share.

This strike price will apply in calculating the number of shares to be issued to participants who have elected to receive additional shares rather than cash.

The strike price has been determined, in accordance with the DRP, as the volume weighted average sale price in New Zealand dollars for Oceania Healthcare shares, calculated on all trades of Oceania Healthcare shares which took place through the NZX Main Board over the period of five trading days starting on 9 February 2021, less a 2.5% discount.

Shareholders who have elected to participate in the DRP will receive shares instead of cash in respect of the dividend payable on 24 February 2021.

The new shares will rank pari passu with existing shares on issue as at the date of their issue.

Please see the link below for details:

DRP Strike Price for 2021 Interim Dividend

Source: Oceania Healthcare Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

19th January 2022 Morning Report
PaySauce Limited (NZX: PYS) Quarterly Market Update Dec 2021
FTX announced as naming rights sponsor of Australian Blockchain Week 2022
18th January 2022 Morning Report
17th January 2022 Morning Report
Mosaic lands leading corporate trust expert as new partner
14th January 2022 Morning Report
13th January 2022 Morning Report
Pictor's completes successful US clinical trials for unique COVID antibody testing
12th January 2022 Morning Report